Tocilizumab Biosimilar (Enzene Biosciences/Theramex)

托珠单抗生物类似药 （Enzene Biosciences/Theramex）

Report date: 2021/12/25 16:40:50

Base Information

Drug NameTocilizumab Biosimilar (Enzene Biosciences/Theramex)
Drug Alias Name托珠单抗生物仿制药 (qyuns)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEnzene Biosciences LtdTheramex
China Registration ClassN/A

Develop Information

Active CompaniesEnzene Biosciences LtdTheramex
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A